Veasey Questions Verst and Kowalski on Clinical Trial Diversity and FDA Novel Endpoint Safeguards
Source: Forbes Breaking News · All Forbes Breaking News reports
Unlock the full scoreboard
Letter grade, factuality, lean, and rationales — free with registration. No card required.
See grades free How grading works
Already have an account? Sign in. The full report below is free to read.
Embed this grade
Disagree with this grade or political lean?
Flagging is open to every reader with a free account. Sign in or create one to dispute this report.
Topics in this report
Summary
Forbes Breaking News clip shows Rep. Marc Veasey questioning witnesses during a July 15, 2026 House Energy and Commerce Subcommittee hearing on FDA's role in biomedical innovation. Veasey asked about expanding clinical trial participation among historically underrepresented communities and safeguards for novel endpoints and biomarkers while preserving evidentiary standards. Dr. Cynthia Verst (IQVIA) discussed recruiting community physicians through interoperable EMR and electronic data capture systems. Dr. Aaron Kowalski (Breakthrough T1D) emphasized a properly staffed FDA, consistent regulations, leading with safety, and clear risk-benefit analysis to support innovation.
Editorial Assessment
The segment faithfully reports the Q&A without added commentary or editing that alters meaning. Viewer may miss broader hearing context, including related legislation like FDORA diversity provisions and ongoing FDA draft guidance on diversity action plans. No loaded language or omitted counterpoints appear; responses reflect standard expert policy views on balancing speed, diversity, and rigor. Sourcing relies on named witnesses testifying under oath.
Key Moments
Congress should ensure modernized trials expand participation in underrepresented communities
Veasey's question aligns with longstanding FDA and congressional priorities, including FDORA 2022 provisions and 2024-2026 draft guidance on diversity action plans.
Interoperable EMR and EDC systems can identify eligible patients via hub-and-spoke models to boost community physician involvement
Verst's testimony matches established strategies discussed in FDA guidance and industry reports on decentralized and community-based trials.
Robust, well-staffed FDA with clear consistent expectations is needed to lead with safety while using novel endpoints and biomarkers
Kowalski's response reflects standard regulatory principles; no factual dispute in the record.
Sources Consulted
- Maintaining America's Leadership in Biomedical Innovation: FDA's Role in Advancing U.S. Drug Development
- Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies
- IQVIA's Dr. Cynthia Verst Testifies Before Congressional Subcommittee
- Food and Drug Omnibus Reform Act of 2022 (FDORA) diversity provisions